Maithel Shishir K, Khalili Korosh, Dixon Elijah, Guindi Maha, Callery Mark P, Cattral Mark S, Taylor Bryce R, Gallinger Steven, Greig Paul D, Grant David R, Vollmer Charles M
Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Stoneman 9, 330 Brookline Avenue, Boston, Massachusetts, 02215, USA.
Ann Surg Oncol. 2007 Jan;14(1):202-10. doi: 10.1245/s10434-006-9041-9.
Two distinct lymph nodes reproducibly assessed by computed tomography for the evaluation of periampullary tumors are the common bile duct (CBD) node and the gastroduodenal artery (GDA) node. We examined whether radiographical enlargement of either lymph node predicts tumor resectability, nodal metastasis, or patient survival.
Ninety-four consecutive patients underwent attempted curative resection of periampullary tumors between September 2001 and June 2003. A single radiologist recorded in a retrospective, blinded fashion the short- and long-axis measurements of the CBD and GDA nodes.
Sixty-one percent (n = 57) of tumors were resectable by pancreaticoduodenectomy. Overall, actual 6-, 12-, and 18-month survival was 87%, 68%, and 63%, respectively. Enlarged radiographical nodal size by either axis was not associated with the presence of metastasis to these lymph nodes or with reduced overall patient survival. Only a CBD node short-axis size >10 mm predicted unresectability (odds ratio, 3.2; P = .036). Liver metastasis and/or carcinomatosis were present in 43% of unresectable patients, and this was associated with decreased survival at both 1 year (25% vs. 77%; P < .001) and 18 months (19% vs. 72%; P <.001). A pathologic diagnosis of metastasis to the GDA node, but not the CBD node, was associated with a similarly decreased survival (1 year: 33% vs. 78%, P = .028; 18 months: 22% vs. 70%, P = .023).
For presumed periampullary malignancy, a CBD node short-axis size >10 mm predicts tumor unresectability. Metastatic disease to the GDA node, particularly for pancreatic adenocarcinoma, portends a poor prognosis equivalent to that of hepatic or peritoneal spread. Given these findings, radiographical CBD lymph node measurements may guide selection for performing laparoscopic staging with or without ultrasonography in conjunction with GDA nodal biopsy in patients with periampullary malignancy.
在通过计算机断层扫描评估壶腹周围肿瘤时,两个可重复性评估的不同淋巴结是胆总管(CBD)淋巴结和胃十二指肠动脉(GDA)淋巴结。我们研究了这两个淋巴结中任何一个的影像学增大是否可预测肿瘤的可切除性、淋巴结转移或患者生存率。
2001年9月至2003年6月期间,连续94例患者尝试进行壶腹周围肿瘤的根治性切除术。一名放射科医生以回顾性、盲法记录了CBD和GDA淋巴结的短轴和长轴测量值。
61%(n = 57)的肿瘤可通过胰十二指肠切除术切除。总体而言,实际6个月、12个月和18个月的生存率分别为87%、68%和63%。任何一个轴上的影像学淋巴结增大与这些淋巴结的转移存在或患者总体生存率降低均无关联。仅CBD淋巴结短轴尺寸>10 mm可预测不可切除性(优势比,3.2;P = .036)。43%的不可切除患者存在肝转移和/或癌性腹膜炎,这与1年(25%对77%;P < .001)和18个月(19%对72%;P <.001)时的生存率降低相关。GDA淋巴结而非CBD淋巴结的转移病理诊断与生存率同样降低相关(1年:33%对78%,P = .028;18个月:22%对70%,P = .023)。
对于疑似壶腹周围恶性肿瘤,CBD淋巴结短轴尺寸>10 mm可预测肿瘤不可切除性。GDA淋巴结转移,尤其是胰腺腺癌,预示着与肝转移或腹膜转移相当的不良预后。基于这些发现,影像学CBD淋巴结测量可能指导在壶腹周围恶性肿瘤患者中选择是否进行腹腔镜分期(有无超声检查)并联合GDA淋巴结活检。